Bayer, J&J win third U.S. Xarelto trial
A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers’ blood thinner Xarelto led to severe internal bleeding.
The verdict in U.S. District Court in Jackson, Mississippi, is a blow to thousands of patients with similar allegations against the drugmaker. The jury returned the verdict after just four hours of deliberation.
The companies also won the previous two trials on claims of risks from Xarelto.
In the latest case, plaintiff Dora Mingo claimed she suffered acute gastrointestinal bleeding after she was treated with Xarelto for a month in 2015 to prevent blood clotting following an operation.
She accused the drugmakers, who jointly developed the blood thinner, of having failed to warn about the bleeding risks and said her injuries could have been prevented had they provided adequate information.
TriMark Legal Funding provides non-recourse pre-settlement and post-settlement Xarelto lawsuit loans to injured plaintiffs nationwide.
This post originally appeared here: https://www.reuters.com/article/us-bayer-xarelto-idUSKCN1AY2GG
Click here to see the full original article.